PDA Journal of GMP and Validation in Japan
Online ISSN : 1881-1728
Print ISSN : 1344-4891
ISSN-L : 1344-4891
Reviews
International Harmonization on the Quality Assurance of Pharmaceuticals
—Concepts and Impacts of ICH Guidelines—
Shigeo KOJIMA
Author information
JOURNALS FREE ACCESS

1999 Volume 1 Issue 1 Pages 18-35

Details
Abstract

  Harmonization of requirements for the regulation of drugs in the world is essential in order to make newly developed pharmaceuticals available all over the world as quickly as possible. For such purpose, ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use) has been organized and actively promoted by 6 parties from three regions (Japan: MHW & JPMA, USA: FAD & PhRMA, EU: CPMP & EFPIA). Quality topics on “Stability Testing, ” “Validation of Analytical Procedures” and “Impurities Testing” has already been finalized among three regions and implemented as the domestic guidelines by the regulatory authority of each member country. Other quality topics on “Specifications,” “GMP on Active Pharmaceutical Ingredients” and “Common Technical Documents” are now under discussion in ICH. In Japan, Revision of General Notices in Japanese Pharmacopoeia is proposed to cope with the concepts of “periodical/skip testing, ” in-process testing” and “parametric release” included in the Step 2 Draft of ICH Speicification Guideline. This article describes the concepts of ICH quality guidelines and their impacts on the regulation for drugs in Japan.

Information related to the author
© 1999 Parenteral Drug Association Japan Chapter
Previous article Next article
feedback
Top